Literature DB >> 25459068

Modified simultaneous integrated boost radiotherapy for unresectable locally advanced breast cancer: preliminary results of a prospective clinical trial.

Takuma Nomiya1, Hiroko Akamatsu2, Mayumi Harada2, Ibuki Ota2, Yasuhito Hagiwara2, Mayumi Ichikawa2, Misako Miwa2, Akihiko Suzuki3, Kenji Nemoto2.   

Abstract

BACKGROUND: The purpose of this study was to evaluate the effect of modified simultaneous integrated boost (SIB) radiotherapy for patients with extensive breast cancer. PATIENTS AND METHODS: Patients with macroscopic tumor and histologically proven adenocarcinoma of the breast were enrolled in the study. Patients were included whether they had or did not have previous surgery, chemotherapy, hormone therapy, or molecular targeted therapy; patients with past history of thoracic radiotherapy were excluded. Under conditions of not exceeding the tolerance dose for normal tissue, irradiation to the tumor was increased to the maximum possible extent using the modified SIB technique.
RESULTS: Three breast cancer patients were treated with the modified SIB technique. All patients were diagnosed as T4b (median maximum diameter of the tumor: 16 cm; range, 15.5-22 cm), and all patients exhibited symptoms because of the extremely large tumor. The median total dose to the part of tumor tissue was 128.8 Gy (range, 110-140 Gy). Total dose to normal tissue was < 72 Gy in all patients. Although large tumors were radio-resistant, it was macroscopically confirmed that all tumors eventually disappeared. Although skin defects persisted because of tumor disappearance, there were no Grade ≥ 3 toxicities due to radiotherapy.
CONCLUSION: Although much care is required in delivering extremely high doses of radiotherapy to the tumor, modified SIB radiotherapy was shown to be effective against extremely large tumors that could not be controlled using conventional radiotherapy. In future, an increase in the number of study patients and establishment of the technique will be required.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast neoplasm; Clinical trial; Radiotherapy; Technique; Unresectable tumor

Mesh:

Year:  2014        PMID: 25459068     DOI: 10.1016/j.clbc.2014.09.011

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  6 in total

1.  Modified simultaneous integrated boost radiotherapy for large retroperitoneal malignant tumor: A case report.

Authors:  Takuma Nomiya; Hiroko Akamatsu; Mayumi Harada; Ibuki Ota; Yasuhito Hagiwara; Mayumi Ichikawa; Misako Miwa; Masaomi Mizutani; Tomoyuki Kato; Akira Nagaoka; Yoshihiko Tomita; Kenji Nemoto
Journal:  Oncol Lett       Date:  2015-04-02       Impact factor: 2.967

2.  Significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma: A care-compliant case report.

Authors:  Young-Hsiang Lin; Shih-Kai Hung; Wen-Yen Chiou; Moon-Sing Lee; Bing-Jie Shen; Liang-Cheng Chen; Dai-Wei Liu; Wei-Ta Tsai; Po-Hao Lin; Yi-Ting Shih; Feng-Chun Hsu; Shiang-Jiun Tsai; Michael W Y Chan; Hon-Yi Lin
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

3.  Radiation treatment planning with embedded dose escalation.

Authors:  William T Hrinivich; Todd R McNutt; Jeffrey J Meyer
Journal:  Radiat Oncol       Date:  2019-08-14       Impact factor: 3.481

4.  Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Drug-Resistant Gastrointestinal Stromal Tumors: A Feasibility Study.

Authors:  Longhao Li; Xin Yi; Haixia Cui; Xuemei Zhao; Jun Dang; Qingfeng Jiang; Ying Li
Journal:  Front Oncol       Date:  2020-11-23       Impact factor: 6.244

Review 5.  Role of modern radiotherapy in managing patients with hepatocellular carcinoma.

Authors:  Liang-Cheng Chen; Hon-Yi Lin; Shih-Kai Hung; Wen-Yen Chiou; Moon-Sing Lee
Journal:  World J Gastroenterol       Date:  2021-05-28       Impact factor: 5.742

6.  Partially ablative radiotherapy (PAR) for large mass tumors using simultaneous integrated boost: A dose-escalation feasibility study.

Authors:  Savino Cilla; Francesco Deodato; Anna Ianiro; Gabriella Macchia; Vincenzo Picardi; Milly Buwenge; Silvia Cammelli; Alice Zamagni; Vincenzo Valentini; Alessio G Morganti
Journal:  J Appl Clin Med Phys       Date:  2018-09-15       Impact factor: 2.102

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.